Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8641181 | 1.00 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL935683 | 1.00 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL30052811 | 1.00 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL30051556 | 0.93 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL30051030 | 0.90 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL15756642 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL29155527 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL8014043 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL29155528 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL8014033 | 0.88 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CA2CA1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709912-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BioAtla, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2024232976-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| US-20240044046-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-02-08 | — | — | US | claimed |
| US-20220282399-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2022-09-08 | — | — | US | claimed |
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | claimed |
| US-20210230221-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, LLC (US) | 2021-07-29 | — | — | US | claimed |
| EP-3565846-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | Bioatla, LLC (US) | 2019-11-13 | — | — | EP | claimed |
| CN-110382543-A | For treating the protein for treatment agent of senile cell | 生物蛋白有限公司 | 2019-10-25 | — | — | CN | claimed |
| EP-2340725-A1 | Methods for the use of branched chain amino acids | Nestec S.A. (CH) | 2011-07-06 | — | — | EP | claimed |
| EP-1957061-B1 | COMBINATION COMPRISING AT LEAST ONE AMINO ACID AND A PKR INHIBITOR FOR USE IN THE TREATMENT OF MUSCLE LOSS | NESTEC SA (CH) | 2011-05-11 | — | — | EP | claimed |
| US-20090170786-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2009-07-02 | — | — | US | claimed |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2009-04-23 | — | — | US | claimed |
| CN-101316582-A | Method of treating muscle loss | NESTEC SA (CH) | 2008-12-03 | — | — | CN | claimed |
| EP-1957061-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2008-08-20 | — | — | EP | claimed |
| EP-1940252-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007064618-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2007-06-07 | — | — | WO | claimed |
| WO-2007053390-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2007-05-10 | — | — | WO | claimed |
| US-6429220-B1 | COMPRISES AN ISOTHIAZOLONE COMPOUND AND AN AMINOCARBOXYLIC ACID | KURITA WATER INDUSTRIES LTD. (JP) | 2002-08-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | BCAT2, CPT1B, BCAT1 | ALDH1A1 3467/4885L3MBTL1 354/4885CA2 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.